Foghorn Therapeutics Inc. (FHTX) Reports In-Line Q1 EPS

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q1 EPS of ($0.73), in-line with the analyst estimate of ($0.73). Revenue for the quarter came in at $5.31 million versus the consensus estimate of $4.22 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI